Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2011 | Review Article

Clinical applications of ¹²⁴I-PET/CT in patients with differentiated thyroid cancer

Authors: Lutz S. Freudenberg, Walter Jentzen, Alexander Stahl, Andreas Bockisch, Sandra J. Rosenbaum-Krumme

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2011

Abstract

¹²⁴I-PET/CT has a high clinical potential in patients with differentiated thyroid cancer (DTC). Two aspects deserve special mention: staging of recurrent or residual disease and pretherapy dosimetry. Used in combination ¹²⁴I-PET and CT allows foci of highly specific ¹²⁴I uptake to be localized with a low radiation dose, which is specifically important in pretherapy diagnostics. In addition in the combination of FDG-PET and CT non-iodine-avid lesions may be detected and may be discriminated from simultaneously occurring iodine-positive lesions. In clinical applications, the pretherapy ¹²⁴I-PET dosimetry may result in a significant alteration in the therapeutic procedure compared to standard therapy using fixed therapeutic activities. In this context, ¹²⁴I-PET dosimetry is a useful procedure especially in advanced DTC, and allows the administration of safer and more effective radioiodine activities as well as earlier multimodal interventions compared to standard empirical protocols. This review summarizes the clinical data on ¹²⁴I-PET/CT in patients with DTC, and addresses future prospects.

Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46:28S–37S.PubMed

Riemann B, Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, et al. Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin. 2010;49(3):79–84.PubMedCrossRef

Biermann M, Pixberg M, Riemann B, Schuck A, Heinecke A, Schmid KW, et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer – results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin. 2009;48(3):89–98.PubMed

Verburg FA, de Keizer B, de Klerk JM, Lentjes EG, Lips CJ, van Isselt JW. Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection. Nuklearmedizin. 2009;48(1):26–9.PubMed

Benua R, Cicale N, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR Am J Roentgenol. 1962;87:171–9.

Sawka AM, Thephamongkhol K, Brouwers M, Thebane H, Browman G, Gerstein HG. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.PubMedCrossRef

Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well differentiated thyroid cancer: a quantitative radiation dosimetric approach – outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–16.PubMed

Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–41.PubMedCrossRef

Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7:183–7.PubMedCrossRef

10.

Kimmig B, Hermann HJ. Measurement of dose during radioiodine treatment of thyroid cancer. Acta Endocrinol. 1983;252 Suppl:72.

11.

Dietlein M, Dressler J, Farahati F, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin. 2004;43:115–20.PubMed

12.

Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9(5):421–7.PubMedCrossRef

13.

Dorn R, Kopp J, Vogt H, et al. Dosimetry guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451–6.PubMed

14.

Furhang EE, Larson SM, Buranapong P, et al. Thyroid cancer dosimetry using clearance fitting. J Nucl Med. 1999;40:131–6.PubMed

15.

Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer. 2010;17(3):R161–72.PubMedCrossRef

16.

Verburg FA, Verkooijen RB, Stokkel MP, van Isselt JW. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin. 2009;48(4):138–42.PubMed

17.

Flower MA, McCready VR. Radionuclide therapy dose calculations: what accuracy can be achieved. Eur J Nucl Med. 1997;24:1462.PubMedCrossRef

18.

Phillips AF, Haybittle JL, Newberry GR. Use of iodine-124 for the treatment of carcinoma of the thyroid. Acta Unio Int Contra Cancrum. 1960;16:1434–8.PubMed

19.

Erdi YE, Macapinlac H, Larson SM, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging. 1999;2:41–6.PubMedCrossRef

20.

Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557–62.PubMed

21.

Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys. 1991;18:357–66.PubMedCrossRef

22.

Freudenberg LS, Antoch G, Knust J, Görges R, Müller SP, Bockisch A, et al. Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092–8.PubMedCrossRef

23.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49(6):1017–23.PubMedCrossRef

24.

Crawford DC, Flower MA, Pratt BE, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med. 1997;24:1470–8.PubMedCrossRef

25.

Freudenberg LS, Bockisch A, Jentzen W. 124I positron emission tomographic dosimetry and positron emission tomography/computed tomography imaging in differentiated thyroid cancer. In: Biersack HJ, Grünwald F, editors. Thyroid cancer. 2nd ed. Berlin: Springer; 2005.

26.

Frey P, Townsend D, Flattet A, et al. Tomographic imaging of the human thyroid using I-124. J Clin Endocrinol Metab. 1986;63:918–27.PubMedCrossRef

27.

Frey P, Townsend D, Jeavons A, et al. In vivo imaging of the human thyroid with a positron camera using 124I. Eur J Nucl Med. 1985;10:472–6.PubMedCrossRef

28.

Lambrecht RM, Woodhouse N, Phillips R, et al. Investigational study of iodine-124 with a positron camera. Am J Physiol Imaging. 1988;3:197–200.PubMed

29.

Sgouros G, Kolbert K, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–72.PubMed

30.

Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37:2267–76.PubMedCrossRef

31.

Jentzen W. Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol. 2010;55(8):2365–98.PubMedCrossRef

32.

Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes. 2010;118(7):393–9.PubMedCrossRef

33.

Stahl AR, Freudenberg L, Bockisch A, Jentzen W. A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(7):1147–55.PubMedCrossRef

34.

O’Connell ME, Flower MA, Hinton PJ, et al. Radiation dose assessment in radioiodine therapy: dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol. 1993;28:16–26.PubMedCrossRef

35.

Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007;46(4):121–8.PubMed

36.

Knust EJ, Dutschka K, Weinreich R. Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot. 2000;52:181–4.PubMedCrossRef

37.

Jentzen W, Freudenberg L, Bockisch A. Quantitative imaging of 124I with PET/CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging. 2011;55:21–43PubMed

38.

Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2008;35(3):611–23.PubMedCrossRef

39.

Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med. 2002;29:760–7.CrossRef

40.

Bockisch A, Freudenberg L, Rosenbaum S, Jentzen W. (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution. Eur J Nucl Med Mol Imaging. 2006;33(11):1247–8.PubMedCrossRef

41.

Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49(12):1952–7.PubMedCrossRef

42.

Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol. 2009;82(982):860–76.PubMedCrossRef

43.

Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(5):958–65.PubMedCrossRef

44.

Capoccetti F, Criscuoli B, Rossi G, Ferretti F, Manni C, Brianzoni E. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009;53(5):536–45.PubMed

45.

Fleming ID, Cooper JS, Henson DE. AJCC cancer staging manual. 5th ed. American Joint Committee on Cancer: Lippincott-Raven, Philadelphia;1997

46.

Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20(8):879–83.PubMedCrossRef

47.

Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35(5):950–7.PubMedCrossRef

48.

Leitha T, Staudenherz A. Frequency of diagnostic dilemmas in 131I whole body scanning. Nuklearmedizin. 2003;42(2):55–62.PubMed

49.

Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging. 2007;34(7):1012–7.PubMedCrossRef

50.

Abdul-Fatah SB, Zamburlini M, Halders SG, Brans B, Teule GJ, Kemerink GJ. Identification of a shine-through artifact in the trachea with (124)I PET/CT. J Nucl Med. 2009;50(6):909–11.PubMedCrossRef

51.

Stewart BW, Kleihues P. Thyroid cancer. In: Stewart BW, Kleihues P, editors. World cancer report. Lyon, France: Lyon. IARC Press; 2003. p. 257–60.

52.

Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer. 1984;53:982–92.PubMedCrossRef

53.

Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993;34:1626–31.PubMed

54.

Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer. 1996;78:2184–92.PubMedCrossRef

55.

Brink JS, Heerden JA, McIver B, et al. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery. 2000;128:881–7.PubMedCrossRef

56.

Sisson JC, Jamadar DA, Kazerooni EA, et al. Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid. 1998;8:215–21.PubMedCrossRef

57.

Ilgan S, Karacalioglu O, Pabuscu Y, et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:825–30.PubMedCrossRef

58.

Freudenberg LS, Jentzen W, Müller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging. 2008;35(3):502–8.PubMedCrossRef

59.

Dietlein M, Busemeyer S, Kobe C, Schmidt M, Theissen P, Schicha H. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma. Nuklearmedizin. 2010;49(6):216–24.CrossRef

60.

Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–85.PubMedCrossRef

61.

Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.PubMedCrossRef

62.

Zanotti-Fregonara P, Hindié E. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(12):2264–6.PubMedCrossRef

63.

Schmitz G, Fuzesi L, Struck J, et al. Expression of the sodium iodide symporter in differentiated thyroid cancer: clinical evidence. Nuklearmedizin. 2005;44:86–93.PubMed

64.

Walter MA, Turtschi CP, Schindler C, et al. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med. 2007;48:1620–5.PubMedCrossRef

65.

Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124)I PET(/CT) imaging. Eur J Nucl Med Mol Imaging. 2010;37:2298–306PubMedCrossRef

66.

Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(5):884–95.PubMedCrossRef

67.

Jentzen W, Schneider E, Freudenberg L, Eising EG, Görges R, Müller SP, et al. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun. 2006;27(8):669–76.PubMedCrossRef

Title: Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer
Authors: Lutz S. Freudenberg
Walter Jentzen
Alexander Stahl
Andreas Bockisch
Sandra J. Rosenbaum-Krumme
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1773-5

At a glance: The STEP trials

Springer Medicine

Clinical applications of ¹²⁴I-PET/CT in patients with differentiated thyroid cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Quantitative imaging of 124I and 86Y with PET

Matched pairs for radionuclide-based imaging and therapy

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

Preclinical animal research on therapy dosimetry with dual isotopes

Absolute quantification in SPECT

Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies